Search results
295 Results for 'Drug Development'
- Technologies (20)
- Team (0)
- News (214)
- Events (0)
- Multimedia (61)
- Publications (0)
- Jobs (0)
Technologies 20
-
Rapid Metabolite-Sensing System for Blood Lactate
In emergency medicine, blood lactate levels are a reliable real-time indicator of the severity and mortality risk of conditions that occur as a result of poor blood circulation and oxygen supply to organs and tissues (hypoperfusion), such as in patients with sepsis, cardiac arrest, stroke, major trauma, cystic fibrosis and other conditions. Lactate levels also... -
DNA Nanotechnology Tools – From Design to Applications
DNA nanostructures with their potential for cell and tissue permeability, biocompatibility, and high programmability at the nanoscale level are promising candidates as new types of drug delivery vehicles, highly specific diagnostic devices, and tools to decipher how biomolecules dynamically change their shapes, and interact with each other and with candidate drugs. Wyss Institute researchers are... -
Using Systems Biology to Find and Test New Drugs Faster
The pharmaceutical industry is infamous for big numbers: it takes 10-15 years and can cost over $2 billion to bring a new drug from the lab to the market. Up to 6 of those years and $1 billion are spent in laborious preclinical trials to identify and validate new potential drug compounds, and much of... -
Controlled Enzymatic RNA Oligonucleotide Synthesis
Synthetic RNA oligonucleotides designed as specific successions of the four nucleobases A, U, G, and C that mimic naturally occurring RNA species are the key components of diverse RNA-based therapies. These include RNA therapeutics that can partially or completely turn off the expression of disease-causing genes (antisense and interfering RNAs), help replace or supplement dysfunctional... -
Brain Targeting Program: Shuttles for Brain Delivery of Therapeutics and Diagnostics
In its Brain Targeting Program, a Wyss team led by Founding Director Donald Ingber, M.D., Ph.D. and Staff Program Lead James Gorman, M.D., Ph.D. is developing improved approaches to target drugs and diagnostics to the brain. Leveraging the human blood-brain barrier (BBB) Chip technology developed by Ingber’s team, combined with advanced antibody R&D capabilities, the... -
CogniXense: Target-Agnostic Drug Repurposing in Record Time
The problem There are more than 7,000 known rare genetic diseases that collectively afflict more patients in the United States than diabetes, but only 5% of these diseases have any effective treatment. A major driver of this lack of therapies is that about 75% of rare genetic diseases cause cognitive and behavioral impairment, which are...
News 214
Multimedia 61
-
Video/AnimationBeating Back the Coronavirus: FDA-Approved Drug Repurposing PipelineWith the goal of rapidly repurposing FDA-approved drugs to treat COVID-19, the Wyss Institute is collaborating with the Frieman Lab at the University of Maryland Medical School and the tenOever Lab at the Icahn School of Medicine at Mount Sinai to establish a multidisciplinary pipeline that can rapidly predict, test, and validate potential treatments. Credit:... -
Video/AnimationBeating Back the CoronavirusWhen the coronavirus pandemic forced Harvard University to ramp down almost all on-site operations, members of the Wyss Institute community refocused their teams, and formed new ones, in order to fight COVID-19 on its multiple fronts. These efforts include building new pieces of personal protective equipment that were delivered to frontline healthcare workers, developing new... -
Video/AnimationCogniXense: Speeding Up Treatments for Rare DiseasesAt the Wyss Institute, we are tackling Rett syndrome, a rare disease that affects 1 out of 9,000 children, by developing a scalable model for neurodevelopmental and cognitive diseases. This model can test drugs to see which will improve memory, learning, and behavior, with the end goal of finding effective therapies. Credit: Wyss Institute at... -
Video/AnimationInterrogator: Human Organ-on-ChipsThis video describes the “Interrogator” instrument that can be programmed to culture up to 10 different Organ Chips and sequentially transfer fluids between their vascular channels to mimic normal human blood flow between the different organs of our body. Its integrated microscope enables the continuous monitoring of the tissues’ integrities in the individual organ chips... -
Video/AnimationAAV Capsid EngineeringWyss researchers have created a high-throughput platform to generate an Adeno-associated virus 2 (AAV2) library containing 200,000 variants, each carrying a distinct mutation in the virus capsid protein. Their analysis identified capsid changes that enhanced “homing” potential to specific organs in mice and virus viability, as well as a new protein hidden in the capsid-encoding... -
Video/AnimationSelf-regenerating bacterial hydrogels as intestinal wound patchesThis animation explains how self-regenerating bacterial hydrogels could be used as adhesive patches to help intestinal wounds heal. Credit: Wyss Institute at Harvard University.